Nifty
Sensex
:
:
24321.05
79739.66
-92.45 (-0.38%)
-409.22 (-0.51%)

Pharmaceuticals & Drugs - Global

Rating :
76/99

BSE: 532321 | NSE: ZYDUSLIFE

1162.45
05-Jul-2024
  • Open
  • High
  • Low
  • Previous Close
  •  1145.00
  •  1166.85
  •  1137.05
  •  1137.05
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  2734011
  •  31633.53
  •  1203.00
  •  567.75

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 118,680.27
  • 30.75
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 118,343.77
  • 0.25%
  • 5.99

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 74.98%
  • 0.64%
  • 5.37%
  • FII
  • DII
  • Others
  • 5.59%
  • 12.53%
  • 0.89%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.49
  • 6.52
  • 8.96

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.69
  • 13.77
  • 10.79

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 12.47
  • 26.50
  • 19.20

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 24.82
  • 24.44
  • 23.22

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.08
  • 3.37
  • 3.31

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.75
  • 14.62
  • 14.54

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Var%
Dec 23
Dec 22
Var%
Sep 23
Sep 22
Var%
Jun 23
Jun 22
Var%
Net Sales
5,533.80
5,010.60
10.44%
4,505.20
4,257.10
5.83%
4,368.80
4,005.50
9.07%
5,139.60
3,964.30
29.65%
Expenses
3,908.60
3,755.00
4.09%
3,423.40
3,406.30
0.50%
3,304.90
3,319.40
-0.44%
3,634.30
3,239.70
12.18%
EBITDA
1,625.20
1,255.60
29.44%
1,081.80
850.80
27.15%
1,063.90
686.10
55.06%
1,505.30
724.60
107.74%
EBIDTM
29.37%
25.06%
24.01%
19.99%
24.35%
17.13%
29.29%
18.28%
Other Income
161.70
37.80
327.78%
58.30
143.70
-59.43%
136.20
173.60
-21.54%
36.00
174.30
-79.35%
Interest
34.60
27.70
24.91%
19.80
32.80
-39.63%
8.70
35.10
-75.21%
18.10
34.30
-47.23%
Depreciation
205.30
178.60
14.95%
194.80
181.60
7.27%
184.20
181.80
1.32%
179.80
180.70
-0.50%
PBT
1,547.00
485.80
218.44%
925.50
780.10
18.64%
1,007.20
642.80
56.69%
1,329.20
681.00
95.18%
Tax
321.20
137.20
134.11%
213.80
195.20
9.53%
226.40
137.00
65.26%
216.10
118.40
82.52%
PAT
1,225.80
348.60
251.64%
711.70
584.90
21.68%
780.80
505.80
54.37%
1,113.10
562.60
97.85%
PATM
22.15%
6.96%
15.80%
13.74%
17.87%
12.63%
21.66%
14.19%
EPS
11.75
2.93
301.02%
7.80
6.16
26.62%
7.91
5.16
53.29%
10.74
5.06
112.25%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Net Sales
-
19,547.40
17,237.40
15,109.90
14,403.50
14,253.10
13,165.60
11,954.50
9,376.50
9,426.80
8,651.30
Net Sales Growth
-
13.40%
14.08%
4.90%
1.06%
8.26%
10.13%
27.49%
-0.53%
8.96%
 
Cost Of Goods Sold
-
5,260.10
5,335.70
4,757.00
4,094.20
4,243.30
4,141.30
3,656.90
3,065.00
2,673.20
2,814.10
Gross Profit
-
14,287.30
11,901.70
10,352.90
10,309.30
10,009.80
9,024.30
8,297.60
6,311.50
6,753.60
5,837.20
GP Margin
-
73.09%
69.05%
68.52%
71.57%
70.23%
68.54%
69.41%
67.31%
71.64%
67.47%
Total Expenditure
-
14,248.40
13,665.50
11,935.20
11,018.20
11,472.90
10,187.20
9,125.90
7,475.00
7,097.30
6,897.40
Power & Fuel Cost
-
366.30
343.50
299.30
231.60
252.90
231.60
211.40
174.50
155.40
145.40
% Of Sales
-
1.87%
1.99%
1.98%
1.61%
1.77%
1.76%
1.77%
1.86%
1.65%
1.68%
Employee Cost
-
2,789.00
2,456.40
2,177.70
2,069.50
2,169.80
1,903.20
1,644.70
1,485.20
1,119.00
1,096.50
% Of Sales
-
14.27%
14.25%
14.41%
14.37%
15.22%
14.46%
13.76%
15.84%
11.87%
12.67%
Manufacturing Exp.
-
2,758.10
2,639.80
2,272.30
2,271.40
2,230.00
1,923.20
1,680.40
955.30
1,397.60
1,136.90
% Of Sales
-
14.11%
15.31%
15.04%
15.77%
15.65%
14.61%
14.06%
10.19%
14.83%
13.14%
General & Admin Exp.
-
625.00
620.30
506.70
444.00
582.60
583.40
398.70
466.00
356.40
326.80
% Of Sales
-
3.20%
3.60%
3.35%
3.08%
4.09%
4.43%
3.34%
4.97%
3.78%
3.78%
Selling & Distn. Exp.
-
1,800.10
1,674.60
1,373.30
1,358.60
1,468.40
1,033.30
1,129.40
826.40
979.60
1,047.20
% Of Sales
-
9.21%
9.71%
9.09%
9.43%
10.30%
7.85%
9.45%
8.81%
10.39%
12.10%
Miscellaneous Exp.
-
649.80
595.20
548.90
548.90
525.90
371.20
404.40
502.60
416.10
1,047.20
% Of Sales
-
3.32%
3.45%
3.63%
3.81%
3.69%
2.82%
3.38%
5.36%
4.41%
3.82%
EBITDA
-
5,299.00
3,571.90
3,174.70
3,385.30
2,780.20
2,978.40
2,828.60
1,901.50
2,329.50
1,753.90
EBITDA Margin
-
27.11%
20.72%
21.01%
23.50%
19.51%
22.62%
23.66%
20.28%
24.71%
20.27%
Other Income
-
369.40
474.60
390.70
47.40
117.10
208.50
133.00
147.10
116.60
57.20
Interest
-
81.20
129.90
127.00
158.80
341.80
195.80
110.80
63.10
52.80
67.90
Depreciation
-
764.10
722.70
713.00
669.60
696.50
598.60
538.80
373.30
292.10
287.30
PBT
-
4,823.10
3,193.90
2,725.40
2,604.30
1,859.00
2,392.50
2,312.00
1,612.20
2,101.20
1,455.90
Tax
-
977.50
587.80
511.70
193.60
319.80
530.30
564.40
128.90
177.40
259.40
Tax Rate
-
20.33%
22.70%
18.03%
8.07%
21.39%
22.26%
24.41%
8.00%
8.45%
17.95%
PAT
-
3,718.10
1,870.30
2,195.40
2,154.20
1,147.80
1,801.90
1,713.00
1,453.90
1,890.90
1,148.50
PAT before Minority Interest
-
3,831.40
2,001.90
2,326.40
2,205.60
1,175.60
1,851.80
1,747.60
1,483.00
1,921.30
1,186.10
Minority Interest
-
-113.30
-131.60
-131.00
-51.40
-27.80
-49.90
-34.60
-29.10
-30.40
-37.60
PAT Margin
-
19.02%
10.85%
14.53%
14.96%
8.05%
13.69%
14.33%
15.51%
20.06%
13.28%
PAT Growth
-
98.80%
-14.81%
1.91%
87.68%
-36.30%
5.19%
17.82%
-23.11%
64.64%
 
EPS
-
36.95
18.59
21.82
21.41
11.41
17.91
17.02
14.45
18.79
11.41

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Shareholder's Funds
19,829.50
17,515.80
16,999.60
12,992.30
10,375.70
10,386.30
8,744.50
6,960.00
5,699.20
4,251.60
Share Capital
100.60
101.20
102.40
102.40
102.40
102.40
102.40
102.40
102.40
102.40
Total Reserves
19,728.90
17,414.60
16,897.20
12,889.90
10,273.30
10,283.90
8,642.10
6,857.60
5,596.80
4,149.20
Non-Current Liabilities
193.10
-725.00
-193.60
19.40
2,853.90
3,491.10
2,122.20
1,903.30
736.10
1,341.50
Secured Loans
0.00
0.00
0.00
0.00
1,953.60
2,332.80
200.60
319.60
393.80
664.00
Unsecured Loans
0.00
0.00
362.10
609.50
1,261.00
1,616.90
2,354.50
2,148.80
502.60
486.40
Long Term Provisions
309.70
271.80
325.00
309.50
235.20
184.10
155.90
151.20
120.70
90.40
Current Liabilities
5,339.70
5,526.70
7,826.80
7,861.30
8,269.40
7,342.50
6,083.00
5,305.80
3,461.00
3,285.10
Trade Payables
2,126.70
2,125.00
2,137.80
2,205.90
2,044.30
1,922.60
1,888.40
1,547.90
1,308.10
1,090.90
Other Current Liabilities
1,677.60
1,798.50
1,967.50
2,166.20
2,126.30
2,033.60
1,484.90
1,212.10
860.70
628.20
Short Term Borrowings
768.60
1,081.00
3,314.10
3,070.90
3,826.50
3,196.90
2,557.50
2,476.90
1,210.90
1,183.50
Short Term Provisions
766.80
522.20
407.40
418.30
272.30
189.40
152.20
68.90
81.30
382.50
Total Liabilities
27,634.40
24,490.00
26,687.00
22,810.30
22,833.70
22,512.80
17,140.70
14,325.20
10,032.10
9,047.10
Net Block
12,368.50
11,520.90
12,188.50
12,132.80
12,230.50
12,163.70
6,482.60
5,755.10
3,747.90
3,352.20
Gross Block
19,919.80
18,343.80
17,650.90
17,345.00
16,781.50
15,702.30
9,349.10
8,102.90
5,767.30
5,138.50
Accumulated Depreciation
7,551.30
6,822.90
5,462.40
5,212.20
4,551.00
3,538.60
2,866.50
2,345.80
2,016.80
1,786.30
Non Current Assets
16,135.20
14,477.60
14,438.20
14,094.30
14,118.30
14,014.70
8,911.00
8,302.90
5,751.70
4,820.40
Capital Work in Progress
2,423.30
1,200.70
725.90
783.20
741.50
837.20
1,527.20
1,543.30
950.80
797.90
Non Current Investment
968.00
927.30
934.80
631.20
552.20
443.60
470.90
385.70
217.10
33.20
Long Term Loans & Adv.
344.50
358.70
369.30
323.30
332.00
410.40
300.00
384.70
661.20
637.10
Other Non Current Assets
30.90
470.00
219.70
223.80
262.10
159.80
130.30
234.10
174.70
0.00
Current Assets
11,419.80
10,008.20
12,095.20
8,716.00
8,715.40
8,498.10
8,229.70
6,022.30
4,280.40
4,226.70
Current Investments
252.50
619.30
2,353.20
198.90
212.80
229.90
274.80
49.10
199.10
121.20
Inventories
3,441.90
3,413.30
3,719.40
3,236.20
2,789.00
2,688.00
2,385.30
1,803.70
1,337.10
1,535.70
Sundry Debtors
5,220.20
4,416.80
3,340.30
3,127.30
3,663.20
3,950.80
3,206.30
2,277.50
1,746.60
1,588.40
Cash & Bank
1,105.10
573.10
1,106.90
888.30
964.90
548.90
1,314.90
1,543.50
638.70
669.90
Other Current Assets
1,400.10
274.00
229.90
523.90
1,085.50
1,080.50
1,048.40
348.50
358.90
311.50
Short Term Loans & Adv.
735.90
711.70
1,345.50
741.40
643.90
584.50
527.70
268.50
234.80
240.80
Net Current Assets
6,080.10
4,481.50
4,268.40
854.70
446.00
1,155.60
2,146.70
716.50
819.40
941.60
Total Assets
27,555.00
24,485.80
26,533.40
22,810.30
22,833.70
22,512.80
17,140.70
14,325.20
10,032.10
9,047.10

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Cash From Operating Activity
3,227.90
2,688.80
2,104.50
3,293.90
2,931.50
1,281.90
919.30
1,311.70
1,893.50
993.60
PBT
4,838.10
2,582.70
5,232.30
2,284.80
1,495.40
2,382.10
2,312.00
1,611.90
2,098.70
1,445.50
Adjustment
546.70
933.90
-2,117.20
1,163.00
1,474.40
539.10
624.30
333.70
249.80
344.50
Changes in Working Capital
-871.10
-235.80
-336.00
191.10
263.80
-971.70
-1,383.90
-411.20
271.70
-377.00
Cash after chg. in Working capital
4,513.70
3,280.80
2,779.10
3,638.90
3,233.60
1,949.50
1,552.40
1,534.40
2,620.20
1,413.00
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,285.80
-592.00
-674.60
-345.00
-302.50
-675.40
-602.30
-237.60
-646.00
-386.90
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.40
7.80
-30.80
14.90
-80.70
-32.50
Cash From Investing Activity
-1,475.20
1,535.00
-1,000.30
-724.60
-1,012.30
-4,238.70
-973.70
-2,871.90
-863.50
-464.70
Net Fixed Assets
-572.20
-669.30
-490.20
-462.80
-289.60
-1,652.30
-600.20
-557.40
-531.50
-271.50
Net Investments
-2,403.70
238.70
1,352.60
-66.50
-2,208.90
-577.10
305.60
-1,606.20
-108.40
-651.40
Others
1,500.70
1,965.60
-1,862.70
-195.30
1,486.20
-2,009.30
-679.10
-708.30
-223.60
458.20
Cash from Financing Activity
-1,810.40
-4,400.40
-868.30
-2,547.70
-1,528.20
1,884.60
51.50
2,315.80
-934.80
-351.10
Net Cash Inflow / Outflow
-57.70
-176.60
235.90
21.60
391.00
-1,072.20
-2.90
755.60
95.20
177.80
Opening Cash & Equivalents
487.80
657.80
888.30
1,177.70
778.80
1,589.70
1,592.60
837.00
737.90
612.60
Closing Cash & Equivalent
413.00
487.80
1,106.90
1,087.20
1,177.70
778.80
1,589.70
1,592.60
837.00
790.40

Financial Ratios

Consolidated /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Book Value (Rs.)
197.11
173.08
166.01
126.88
101.33
101.43
85.40
67.97
55.66
41.52
ROA
14.70%
7.82%
9.40%
9.66%
5.18%
9.34%
11.11%
12.18%
20.14%
13.93%
ROE
20.52%
11.60%
15.51%
18.88%
11.32%
19.36%
22.26%
23.43%
38.62%
30.85%
ROCE
24.90%
13.64%
15.30%
14.23%
10.02%
15.89%
18.41%
16.50%
28.60%
23.21%
Fixed Asset Turnover
1.98
1.88
1.69
1.69
0.88
1.05
1.38
1.38
1.76
1.80
Receivable days
46.37
41.75
39.94
42.92
97.49
99.21
83.37
76.72
63.29
56.38
Inventory Days
32.98
38.39
42.95
38.08
70.13
70.33
63.69
59.88
54.52
60.13
Payable days
147.51
145.80
166.64
189.45
64.85
68.81
68.11
74.18
65.30
55.05
Cash Conversion Cycle
-68.16
-65.67
-83.76
-108.45
102.77
100.73
78.94
62.42
52.51
61.46
Total Debt/Equity
0.04
0.07
0.25
0.35
0.77
0.76
0.62
0.75
0.43
0.62
Interest Cover
60.22
20.94
23.35
16.11
5.38
13.17
21.87
26.55
40.75
22.29

News Update:


  • Zydus Lifesciences gets USFDA’s final approval for Valsartan Tablets
    23rd Jul 2024, 12:10 PM

    Valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure in adults and paediatric patients one year of age and older

    Read More
  • Zydus Lifesciences gets nod to market Bhava to treat various cancers
    22nd Jul 2024, 09:42 AM

    Zydus had developed and launched the Bevacizumab biosimilar developed in-house by the research team at the Zydus Research Centre in 2015 in India under the brand name Bryxta

    Read More
  • Zydus Lifesciences gets USFDA’s final approval for Zituvimet XR extended-release tablets
    19th Jul 2024, 12:30 PM

    The product will be manufactured at the group’s formulation manufacturing facility in Ahmedabad SEZ, India

    Read More
  • USFDA classifies Zydus Lifesciences’ Jarod unit as 'official action indicated'
    19th Jul 2024, 10:29 AM

    The company will work closely with the agency to resolve the regulatory status of this facility expeditiously

    Read More
  • Zydus Lifesciences enters into patent licensing agreement with Takeda Pharmaceutical
    18th Jul 2024, 11:00 AM

    The drug will be marketed under the brand name Vault in the country

    Read More
  • Zydus Lifesciences gets USFDA’s tentative approval for Diroximel Fumarate Delayed-Release Capsules
    10th Jul 2024, 16:13 PM

    The drug will be manufactured at the group’s formulation manufacturing facility in Ahmedabad SEZ, India

    Read More
  • Zydus Lifesciences gets USFDA’s tentative approval for Azilsartan Medoxomil Tablets
    4th Jul 2024, 15:00 PM

    Azilsartan is an angiotensin II receptor blocker (ARB) indicated for the treatment of hypertension to lower blood pressure

    Read More
  • Zydus Lifesciences inks licensing agreement with Dr. Reddy’s Laboratories
    29th Jun 2024, 14:48 PM

    Under the terms of this agreement, Dr. Reddy’s will receive semi-exclusive rights from Zydus to co-market the product in India

    Read More
  • Zydus Lifesciences gets USFDA’s tentative nod for Azilsartan Medoxomil and Chlorthalidone Tablets
    14th Jun 2024, 14:45 PM

    Azilsartan Medoxomil and Chlorthalidone Tablets had annual sales of $77.9 million in the United States

    Read More
  • Zydus Lifesciences gets final approval from USFDA for Theophylline Extended-Release Tablets
    22nd May 2024, 12:40 PM

    The drug will be manufactured at the group’s formulation manufacturing facility in Ahmedabad SEZ, India

    Read More
  • Zydus Lifesciences reports 3- fold jump in Q4 consolidated net profit
    17th May 2024, 16:23 PM

    Total consolidated income of the company increased by 12.71% at Rs 5690.20 crore for Q4FY24

    Read More
  • Zydus Lifesciences - Quarterly Results
    17th May 2024, 15:40 PM

    Read More
  • Zydus Lifesciences’ arm signs exclusive licensing, supply agreement with MSN Laboratories
    17th May 2024, 09:28 AM

    As per the terms of the agreement, MSN Laboratories will be in charge of manufacturing and supplying the generic version of CABOMETYX, following the receipt of regulatory approval

    Read More
  • Zydus Lifesciences gets final approval from USFDA for Dexamethasone Tablets
    11th May 2024, 15:20 PM

    The product will be manufactured at the group’s formulation manufacturing facility at Baddi, Himachal Pradesh

    Read More
  • Zydus Lifesciences gets USFDA’s approval for Dapsone Gel
    9th May 2024, 12:46 PM

    Dapsone Gel, 7.5% had annual sales of $35.8 million in the United States

    Read More
  • Zydus Lifesciences’ arm acquires worldwide proprietary rights to Zokinvy
    4th May 2024, 16:06 PM

    Zokinvy is approved in the U.S. (2020), European Union and Great Britain (2022), and Japan (2024) for the treatment of Progeria

    Read More
  • Zydus Lifesciences gets USFDA’s final approval for Tretinoin Cream
    26th Apr 2024, 14:24 PM

    The drug will be manufactured at the group’s topical manufacturing facility at Changodar, Ahmedabad, India

    Read More
  • USFDA concludes inspection at Zydus Lifesciences’ Vadodara manufacturing site
    24th Apr 2024, 10:15 AM

    The inspection closed with 10 observations

    Read More
  • Zydus Lifesciences gets nod for new drug application of Desidustat Tablets
    23rd Apr 2024, 14:58 PM

    The company has received approval from National Medical Products Administration of China

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.